Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
1
|
Inhibition of mutated, activated BRAF in metastatic melanoma.
|
N Engl J Med
|
2010
|
36.57
|
2
|
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.
|
Nature
|
2010
|
16.12
|
3
|
COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer.
|
Nucleic Acids Res
|
2009
|
9.59
|
4
|
RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.
|
Cancer Res
|
2010
|
4.70
|
5
|
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.
|
Lancet
|
2008
|
3.62
|
6
|
Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.
|
J Transl Med
|
2010
|
2.65
|
7
|
Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer.
|
J Clin Oncol
|
2008
|
2.57
|
8
|
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.
|
J Clin Oncol
|
2012
|
2.42
|
9
|
Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.
|
Clin Pharmacol Ther
|
2000
|
1.86
|
10
|
Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
|
Lancet
|
2005
|
1.60
|
11
|
Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma.
|
Clin Cancer Res
|
2009
|
1.52
|
12
|
Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma.
|
J Natl Cancer Inst
|
2016
|
1.40
|
13
|
Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma.
|
Oncotarget
|
2014
|
1.33
|
14
|
Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation.
|
Cancer
|
2002
|
1.20
|
15
|
Effective inhibition of cell growth and invasion of melanoma by combined suppression of BRAF (V599E) and Skp2 with lentiviral RNAi.
|
Int J Cancer
|
2006
|
1.09
|
16
|
Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment.
|
Front Immunol
|
2015
|
1.04
|
17
|
BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.
|
Onco Targets Ther
|
2015
|
0.99
|
18
|
Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901.
|
Mol Cancer Ther
|
2008
|
0.96
|
19
|
Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma.
|
Cancer Biol Med
|
2014
|
0.95
|
20
|
Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.
|
Cancer
|
2006
|
0.91
|
21
|
Understanding the biology of melanoma and therapeutic implications.
|
Hematol Oncol Clin North Am
|
2014
|
0.85
|
22
|
Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy.
|
Semin Oncol
|
2015
|
0.82
|
23
|
The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies.
|
Trends Immunol
|
2016
|
0.75
|